ALLR
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.
Allarity Therapeutics, Inc. (ALLR) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Growth (D-). The rating has held at C- for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.8) | D- (0.8) | C- (2.1) | D+ (1.6) | C+ (2.6) | C- (2.0) |
| 2026-11-10 | C+ (2.7) | D- (0.8) | C- (2.1) | D+ (1.6) | C+ (2.6) | C- (2.0) |
| 2026-11-03 | C+ (2.7) | D- (0.8) | C- (2.1) | C- (2.1) | C+ (2.7) | C- (2.1) |
| 2026-10-27 | C+ (2.8) | D- (0.8) | C- (2.0) | D+ (1.8) | C+ (2.6) | C- (2.0) |
| 2026-10-20 | C+ (2.8) | D- (0.8) | C- (2.0) | C- (2.1) | C+ (2.6) | C- (2.1) |